0
Industry
Geography
Report Type
Themes
Price
Publication date
Published Date
  • Innovation Ranking

    $1,995 | March 2024
    Innovation Ranking

    Innovation Ranking – Corvus Pharmaceuticals Inc

    Corvus Pharmaceuticals Inc (Corvus Pharma) is a clinical-stage biopharmaceutical company. It is engaged in the development and commercialization of immuno-oncology therapies that are used for treating cancer. Corvus Pharma's product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in phase I clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine produced by the tumor cells. Corvus Pharma’s product pipeline...

  • Innovation Ranking

    $1,995 | March 2024
    Innovation Ranking

    Innovation Ranking – TRACON Pharmaceuticals Inc

    TRACON Pharmaceuticals Inc (TRACON) is a biopharmaceutical company. It develops and commercializes targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. The company offers pipeline products such as TRC105, TRC102, TJ004309, TRC253, TRC694, and TRC205. Its lead product TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with VEGF inhibitors. TRC102 is a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. In...

  • Innovation Ranking

    $1,995 | March 2024
    Innovation Ranking

    Innovation Ranking – Agios Pharmaceuticals Inc

    Agios Pharmaceuticals Inc (Agios) is a biopharmaceutical company. The company focuses on the discovery and development of investigational medicines for the treatment of cancer and rare genetic metabolic disorders. Its pipeline products include AG-946, a novel, next-generation PKR activator used for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low- to intermediate-risk myelodysplastic syndrome. The company also provides Mitapivat which is an activator of both wild-type and a variety of mutant pyruvate kinase that...

  • Innovation Ranking

    $1,995 | March 2024
    Innovation Ranking

    Innovation Ranking – Eagle Pharmaceuticals Inc

    Eagle Pharmaceuticals Inc (Eagle) is a specialty pharmaceutical company that offers proprietary pharmaceutical injectables in the therapy areas of critical care, oncology, and various orphan diseases. The company’s key commercial products encompass pharmaceutical injectables, including Ryanodex for exertional heatstroke; Bendeka, and Belrapzo, both for the treatment of chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin’s lymphoma (NHL). Pipeline products of the company include EP-4104 (dantrolene sodium) for exertional heat stroke (EHS) and nerve agent exposure; EA-114 (fulvestrant) for the treatment...

  • Innovation Ranking

    $1,995 | March 2024
    Innovation Ranking

    Innovation Ranking – X4 Pharmaceuticals Inc

    X4 Pharmaceuticals Inc, formerly Arsanis Inc, is a clinical stage bio pharmaceutical company that develops oral, small molecule therapeutics to treat cancer and rare diseases. The company’s pipeline products include Mavorixafor, an allosteric inhibitor of CXCR4 for the treatment of Warts, Hypogammaglobulinemia, Immunodeficiency and Myelokathexis (WHIM) syndrome X4P-002 and X4P-003, small molecule antagonists of chemokine receptor CXCR4 for treating glioblastoma multiforme and primary immune deficiencies (PI's). The company is developing oral allosteric antagonists of CXCR4 in order to block overstimulation...

  • Innovation Ranking

    $1,995 | March 2024
    Innovation Ranking

    Innovation Ranking – Intercept Pharmaceuticals Inc

    Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops, and commercializes treatments for non-viral, progressive liver diseases. It develops products using proprietary bile acid chemistry. The company’s lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor. The company is advancing OCA for the treatment of various other liver diseases. The company harnesses its proprietary bile acid chemistry to develop innovative drugs. It is also advancing INT-787, an FXR...

  • Innovation Ranking

    $1,995 | March 2024
    Innovation Ranking

    Innovation Ranking – Dechra Pharmaceuticals Plc

    Dechra Pharmaceuticals Plc (Dechra) is a manufacturer and distributor of veterinary pharmaceutical products. The company's product portfolio includes amoxicillin, carprovet, cefpoderm, clavacillin, dexmedesed, enrofloxacin, enroquin, gentaCalm, isoflurane_x000D_ laverdia, marboquim, meloxicam, muricin, ophtHAvet, orthokine , osurnia, rederox, sevoflurane, tzed, vetivex, vetoryl, vetropolycin , zenalpha and zycortal, among others. Its products are used in the therapeutic areas of anesthesia and analgesia, dermatology, pet diets and nutrition, endocrinology, cardiology, exotics and fluid therapy. Dechra manufactures human and veterinary pharmaceutical products for third-party customers....

  • Innovation Ranking

    $1,995 | March 2024
    Innovation Ranking

    Innovation Ranking – EyeGate Pharmaceuticals Inc

    Kiora Pharmaceuticals Inc (Kiora), formerly EyeGate Pharmaceuticals Inc, is a clinical-stage specialty pharmaceutical and drug delivery company that develops and commercializes products for treating diseases and disorders of the eye. The company's pipeline consists of three product candidates, including KIO-101, KIO-301, and KIO-201. Its lead product, KIO-301, is a potential vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases. KIO-101 is a non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) that...

  • Innovation Ranking

    $1,995 | March 2024
    Innovation Ranking

    Innovation Ranking – Clinuvel Pharmaceuticals Ltd

    Clinuvel Pharmaceuticals Ltd (Clinuvel Pharmaceuticals) is a biopharmaceutical company which focuses on the development of drugs for the treatment of light related severe skin disorders. The company’s lead product candidate, Scenesse (afamelanotide) is a first-in-class drug targeting erythropoietic protoporphyria (EPP) and is approved in Europe, Australia and the US for treating adult EPP patients. Its other products under development includes CUV9900 and VLRX001 among others. Clinuvel Pharmaceuticals also focused on developing a pediatric formulation of Scenesse for EPP and OTC...

  • Innovation Ranking

    $1,995 | March 2024
    Innovation Ranking

    Innovation Ranking – NeuroBo Pharmaceuticals Inc

    NeuroBo Pharmaceuticals Inc (NeuroBo), formerly Gemphire Therapeutics Inc, is a clinical stage biopharmaceutical company that focuses on developing novel therapeutics for neurodegenerative and cardiometabolic diseases. The company has pipeline product candidates include ANA001, an oral niclosamide formulation developed for moderate coronavirus disease (COVID-19 which is phase 2 clinical trials. Gemcabene for the treatment of homozygous familial hypercholesterolemia (HoFH) and hypertriglyceridemia (SHTG) which is a serious medical condition that increases the risk of life-threatening cardiovascular diseases; NB-01 for painful diabetic neuropathy...

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.